[go: up one dir, main page]

WO2000064483A3 - Releasable linkage and compositions containing same - Google Patents

Releasable linkage and compositions containing same Download PDF

Info

Publication number
WO2000064483A3
WO2000064483A3 PCT/US2000/010830 US0010830W WO0064483A3 WO 2000064483 A3 WO2000064483 A3 WO 2000064483A3 US 0010830 W US0010830 W US 0010830W WO 0064483 A3 WO0064483 A3 WO 0064483A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions containing
containing same
releasable linkage
linkage
releasable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/010830
Other languages
French (fr)
Other versions
WO2000064483A2 (en
Inventor
Samuel Zalipsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ514990A priority Critical patent/NZ514990A/en
Application filed by Alza Corp filed Critical Alza Corp
Priority to IL14604700A priority patent/IL146047A0/en
Priority to EP00923572A priority patent/EP1173221A2/en
Priority to JP2000613473A priority patent/JP2002542386A/en
Priority to PCT/US2000/010830 priority patent/WO2000064483A2/en
Priority to MXPA01010751A priority patent/MXPA01010751A/en
Priority to AU43672/00A priority patent/AU770390B2/en
Priority to CA002368793A priority patent/CA2368793A1/en
Publication of WO2000064483A2 publication Critical patent/WO2000064483A2/en
Publication of WO2000064483A3 publication Critical patent/WO2000064483A3/en
Priority to NO20015169A priority patent/NO20015169L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

A compound comprised of a hydrophilic polymer covalently yet reversibly linked to an amine-containing ligand through a dithiobenzyl linkage is described.
PCT/US2000/010830 1999-04-23 2000-04-21 Releasable linkage and compositions containing same Ceased WO2000064483A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002368793A CA2368793A1 (en) 1999-04-23 2000-04-21 Releasable linkage and compositions containing same
IL14604700A IL146047A0 (en) 1999-04-23 2000-04-21 Releasable linkage and compositions containing same
EP00923572A EP1173221A2 (en) 1999-04-23 2000-04-21 Releasable linkage and compositions containing same
JP2000613473A JP2002542386A (en) 1999-04-23 2000-04-21 Releasable bonds and compositions containing the same
PCT/US2000/010830 WO2000064483A2 (en) 1999-04-23 2000-04-21 Releasable linkage and compositions containing same
NZ514990A NZ514990A (en) 1999-04-23 2000-04-21 Releasable linkage and compositions containing same
AU43672/00A AU770390B2 (en) 1999-04-23 2000-04-21 Releasable linkage and compositions containing same
MXPA01010751A MXPA01010751A (en) 1999-04-23 2000-04-21 Releasable linkage and compositions containing same.
NO20015169A NO20015169L (en) 1999-04-23 2001-10-23 Compound with reversible bond and preparation comprising the compound

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13089799P 1999-04-23 1999-04-23
US60/130,897 1999-04-23
PCT/US2000/010830 WO2000064483A2 (en) 1999-04-23 2000-04-21 Releasable linkage and compositions containing same

Publications (2)

Publication Number Publication Date
WO2000064483A2 WO2000064483A2 (en) 2000-11-02
WO2000064483A3 true WO2000064483A3 (en) 2001-08-02

Family

ID=34107071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010830 Ceased WO2000064483A2 (en) 1999-04-23 2000-04-21 Releasable linkage and compositions containing same

Country Status (8)

Country Link
EP (1) EP1173221A2 (en)
JP (1) JP2002542386A (en)
AU (1) AU770390B2 (en)
CA (1) CA2368793A1 (en)
IL (1) IL146047A0 (en)
NO (1) NO20015169L (en)
NZ (1) NZ514990A (en)
WO (1) WO2000064483A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1880736A1 (en) 1999-04-23 2008-01-23 Alza Corporation Releasable linkage and composition containing same
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
CN100479862C (en) 2000-04-03 2009-04-22 参天制药株式会社 Transporters and drug delivery system by using the same
JP2004525138A (en) * 2001-03-26 2004-08-19 アルザ・コーポレーシヨン Liposomal compositions for improved intracellular delivery of therapeutic agents
CN1867580B (en) * 2003-09-03 2010-09-29 协和发酵麒麟株式会社 Compounds modified with glycerol derivatives
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US11319408B2 (en) 2017-03-30 2022-05-03 Nof Corporation Hydrophilic polymer derivative having self-immolative acetal linker and conjugate using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891468A (en) * 1996-10-11 1999-04-06 Sequus Pharmaceuticals, Inc. Fusogenic liposome compositions and method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952394A (en) * 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891468A (en) * 1996-10-11 1999-04-06 Sequus Pharmaceuticals, Inc. Fusogenic liposome compositions and method

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
GABER MOHAMED H ET AL: "Thermosensitive sterically stabilized liposomes: Formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma.", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 12, no. 10, 1995, pages 1407 - 1416, XP000979539, ISSN: 0724-8741 *
HIROTA SADAO: "Physicochemical specification of drug carrying liposomes for the quality control in the industrial production.", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 162, no. 1-2, 20 March 1998 (1998-03-20), pages 185 - 194, XP000979551, ISSN: 0378-5173 *
JOHNSSON MARKUS ET AL: "Optimization of drug loading procedures and characterization of liposomal formulations of two novel agents intended for boron neutron capture therapy (BNCT).", JOURNAL OF LIPOSOME RESEARCH, vol. 9, no. 1, February 1999 (1999-02-01), pages 53 - 79, XP000805700, ISSN: 0898-2104 *
KIRPOTIN DMITRI ET AL: "Liposomes with detachable polymer coating: Destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol).", FEBS LETTERS, vol. 388, no. 2-3, 1996, pages 115 - 118, XP002080855, ISSN: 0014-5793 *
MUELLER C E ET AL: "AMPHIPHILIC UNSYMMETRICAL DISULFIDES AS BILAYER-FORMING COMPOUNDS", ARCHIV DER PHARMAZIE (WEINHEIM), vol. 322, no. 6, 1989, pages 343 - 350, XP000981914, ISSN: 0365-6233 *
VAAGE J ET AL: "THERAPY OF PRIMARY AND METASTATIC MOUSE MAMMARY CARCINOMAS WITH DOXORUBICIN ENCAPSULATED IN LONG CIRCULATING LIPOSOMES", INTERNATIONAL JOURNAL OF CANCER, vol. 51, no. 6, 1992, pages 942 - 948, XP000979548, ISSN: 0020-7136 *
VAAGE JAN ET AL: "Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes.", INTERNATIONAL JOURNAL OF CANCER, vol. 80, no. 1, 5 January 1999 (1999-01-05), pages 134 - 137, XP000979545, ISSN: 0020-7136 *
VAAGE JAN ET AL: "Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes.", CANCER (PHILADELPHIA), vol. 72, no. 12, 1993, pages 3671 - 3675, XP000979540, ISSN: 0008-543X *
VAAGE JAN ET AL: "Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts.", CANCER (PHILADELPHIA), vol. 73, no. 5, 1994, pages 1478 - 1484, XP000979547, ISSN: 0008-543X *
ZALIPSKY SAMUEL ET AL: "New detachable poly(ethylene glycol) conjugates: Cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine.", BIOCONJUGATE CHEMISTRY, vol. 10, no. 5, 20 September 1999 (1999-09-20), pages 703 - 707, XP002159601, ISSN: 1043-1802 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same

Also Published As

Publication number Publication date
WO2000064483A2 (en) 2000-11-02
NZ514990A (en) 2004-01-30
CA2368793A1 (en) 2000-11-02
EP1173221A2 (en) 2002-01-23
IL146047A0 (en) 2002-07-25
NO20015169L (en) 2001-12-19
JP2002542386A (en) 2002-12-10
NO20015169D0 (en) 2001-10-23
AU770390B2 (en) 2004-02-19
AU4367200A (en) 2000-11-10

Similar Documents

Publication Publication Date Title
IL146055A0 (en) Conjugate having a cleavable linkage for use in a liposome
CA2152640A1 (en) Cosmetic Compositions with Keratolytic and Anti-Acne Activity
CA2395331A1 (en) Pharmaceutical compositions providing enhanced drug concentrations
CA2197188A1 (en) Denture adhesive
CA2316834A1 (en) Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
CA2222535A1 (en) Oxygen-scavenging composition
CA2131547A1 (en) Composition for oral preparations
CA2307607A1 (en) Powdery nasal compositions
CA2181172A1 (en) Storage-stable prostaglandin compositions
CA2268433A1 (en) Improved interferon polymer conjugates
CA2327723A1 (en) Bicyclic hydroxamic acid derivatives
CA2195426A1 (en) Aqueous silane adhesive compositions
CA2203895A1 (en) Denture stabilizing compositions
CA2169401A1 (en) Components and catalysts for the polymerization of olefins
EP1714664A3 (en) Superabsorbent polymer containing triclosan as odor-controlling compound
CA2206532A1 (en) Novel amidinonaphthyl derivative or salt thereof
CA2392790A1 (en) Operator selected maximum speed and recalibrated pedal range for a vehicle
WO2001044215A3 (en) Fungicidal combinations of active substances
WO2000064483A3 (en) Releasable linkage and compositions containing same
AU2268301A (en) Novel urea compounds, compositions and methods of use and preparation
AU5076799A (en) Trifunctional reagent for conjugation to a biomolecule
CA2439362A1 (en) Furfuryl alcohol and lignin adhesive composition
EP1003526A4 (en) Covalently linked n,o-carboxymethylchitosan and uses thereof
WO2002096372A3 (en) Topical composition comprising an activated, trans-structured cosmetic bonding agent
EP0744171A4 (en) Dental composition for hypersensitive dentin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807707.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2368793

Country of ref document: CA

Ref document number: 2368793

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 613473

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/08724

Country of ref document: ZA

Ref document number: 514990

Country of ref document: NZ

Ref document number: PA/a/2001/010751

Country of ref document: MX

Ref document number: 200108724

Country of ref document: ZA

Ref document number: 1020017013588

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000923572

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017013588

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000923572

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1020017013588

Country of ref document: KR